SciELO - Scientific Electronic Library Online

 
vol.32 issue4Indications for head computed tomography in patients younger than 2 years old with minor head injuriesRestless leg syndrome (Willis-Ekbom Disease) author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Acta Neurológica Colombiana

Print version ISSN 0120-8748

Abstract

OTALORA-ESTEBA, Margarita et al. Rivastigmine patches alone or combined with memantine compared with memantine alone in patients with moderate to severe Alzheimer's disease: Systematic review of the literature. Acta Neurol Colomb. [online]. 2016, vol.32, n.4, pp.337-346. ISSN 0120-8748.  http://dx.doi.org/10.22379/24224022118.

Summary Introduction: Alzheimer's disease (AD), an irreversible, progressive neurodegenerative condition, is the most common cause of dementia and generates a high economic burden. The aim of this study was to conduct a systematic review of the literature to determine the safety and efficacy of rivastigmine patch, alone or in combination with memantine, compared with memantine monotherapy for the treatment of moderate to severe AD. Methods: A systematic search of the literature was conducted. Including randomized controlled trials of patients diagnosed with moderate to severe AD, evaluating outcomes of effectiveness and safety. Results: The results of experimental studies comparing doses of rivastigmine patches indicate a possible difference in some of the outcomes of effectiveness such as performance in activities of daily living, instrumental activities, and overall functioning, in patients with moderate and severe AD, without significant difference in safety outcomes. A trend in favor of combination therapy in some of the outcomes, as change in MMSE score and instrumental daily activities, was observed. Discussion: The available evidence supports the use of rivastigmine, and the association with memantine seems an appropriate therapeutic option in selected cases.

Keywords : Alzheimer disease; holinesterase inhibitors; consumer product safety; memantine; review; treatment outcome.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License